{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:41:49Z","timestamp":1781534509340,"version":"3.54.5"},"reference-count":242,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MedScience"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The unprecedented success of mRNA vaccines during the COVID-19 pandemic has accelerated the development of nucleic acid\u2013based therapeutics, particularly in oncology. Decades of foundational research on mRNA design, delivery, and immunogenicity have laid the groundwork for the application of mRNA vaccines in cancer treatment. Herein, we summarize the key principles of synthetic mRNA engineering, including the optimization of structural elements, nucleoside modification, and codon usage to improve stability, enhance translation efficiency, and modulate immune responses. We highlight diverse antigen strategies, including tumor-associated antigens; neoantigens; and novel sources, such as cryptic antigens, aberrant splicing variants, and transposable element-derived antigens. We discuss delivery platforms, particularly lipid nanoparticles (LNPs) and dendritic cell-based systems, in the context of improving mRNA biodistribution and immune activation. We further examine how mRNA vaccines stimulate antitumor responses by encoding antigens, modulating the tumor microenvironment, and supporting adoptive T cell therapies. We review preclinical and clinical advances in combining mRNA vaccine with immune checkpoint inhibitors for the treatment of solid tumors (e.g., melanoma, pancreatic cancer, and glioblastoma) and hematologic malignancies (e.g., acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma). Finally, we explore emerging innovations, such as targeted LNP platforms for\n                    <jats:italic>in vivo<\/jats:italic>\n                    chimeric antigen receptor T\/T cell receptor T engineering and artificial intelligence\u2013assisted vaccine design, underscoring the transformative potential of mRNA technology in cancer immunotherapy.\n                  <\/jats:p>","DOI":"10.1007\/s11684-026-1210-6","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:21:25Z","timestamp":1775035285000},"page":"23-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies"],"prefix":"10.1007","volume":"20","author":[{"given":"Niu","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"3","key":"1210_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1210_CR2","first-page":"8","volume":"74","author":"DS Dizon","year":"2024","unstructured":"Dizon DS, Kamal AH. Cancer statistics 2024: all hands on deck. CA Cancer J Clin 2024; 74(1): 8\u20139","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1210_CR3","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S1470-2045(23)00412-6","volume":"24","author":"C Are","year":"2023","unstructured":"Are C, Murthy SS, Sullivan R, Schissel M, Chowdhury S, Alatise O, Anaya D, Are M, Balch C, Bartlett D, Brennan M, Cairncross L, Clark M, Deo SVS, Dudeja V, D\u2019Ugo D, Fadhil I, Giuliano A, Gopal S, Gutnik L, Ilbawi A, Jani P, Kingham TP, Lorenzon L, Leiphrakpam P, Leon A, Martinez-Said H, McMasters K, Meltzer DO, Mutebi M, Zafar SN, Naik V, Newman L, Oliveira AF, Park DJ, Pramesh CS, Rao S, Subramanyeshwar Rao T, Bargallo-Rocha E, Romanoff A, Rositch AF, Rubio IT, Salvador de Castro Ribeiro H, Sbaity E, Senthil M, Smith L, Toi M, Turaga K, Yanala U, Yip CH, Zaghloul A, Anderson BO. Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide. Lancet Oncol 2023; 24(12): e472\u2013e518","journal-title":"Lancet Oncol"},{"issue":"6","key":"1210_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","volume":"22","author":"M Labrie","year":"2022","unstructured":"Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer 2022; 22(6): 323\u2013339","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1210_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/cancers14030627","volume":"14","author":"WMC van den Boogaard","year":"2022","unstructured":"van den Boogaard WMC, Komninos DSJ, Vermeij WP. Chemotherapy side-effects: not all DNA damage is equal. Cancers (Basel) 2022; 14(3): 627","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1210_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, R\u00f6llig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, L\u00f6wenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140(12): 1345\u20131377","journal-title":"Blood"},{"key":"1210_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drup.2019.07.004","volume":"45","author":"E Kon","year":"2019","unstructured":"Kon E, Benhar I. Immune checkpoint inhibitor combinations: current efforts and important aspects for success. Drug Resist Updat 2019; 45: 13\u201329","journal-title":"Drug Resist Updat"},{"issue":"5","key":"1210_CR8","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019Byrne K, Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Curr Oncol 2022; 29(5): 3044\u20133060","journal-title":"Curr Oncol"},{"issue":"7","key":"1210_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","volume":"6","author":"Q Duan","year":"2020","unstructured":"Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer 2020; 6(7): 605\u2013618","journal-title":"Trends Cancer"},{"issue":"5","key":"1210_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","volume":"7","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Zehir A, Berger MF, Seshan VE, Chan TA, Morris LGT. Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase. JAMA Oncol 2021; 7(5): 739\u2013743","journal-title":"JAMA Oncol"},{"issue":"1","key":"1210_CR11","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 2020; 11(1): 3801","journal-title":"Nat Commun"},{"issue":"7876","key":"1210_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","volume":"597","author":"E Dolgin","year":"2021","unstructured":"Dolgin E. The tangled history of mRNA vaccines. Nature 2021; 597(7876): 318\u2013324","journal-title":"Nature"},{"issue":"6","key":"1210_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol 2022; 40(6): 840\u2013854","journal-title":"Nat Biotechnol"},{"issue":"11","key":"1210_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov 2021; 20(11): 817\u2013838","journal-title":"Nat Rev Drug Discov"},{"issue":"7830","key":"1210_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Sch\u00e4fer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Alvarado GS, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 2020; 586(7830): 567\u2013571","journal-title":"Nature"},{"issue":"10","key":"1210_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics\u2014developing a new class of drugs. Nat Rev Drug Discov 2014; 13(10): 759\u2013780","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1210_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022; 7(1): 166","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"1210_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","volume":"21","author":"EJ Sayour","year":"2024","unstructured":"Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol 2024; 21(7): 489\u2013500","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1210_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discov 2024; 23(4): 281\u2013300","journal-title":"Nat Rev Drug Discov"},{"issue":"10432","key":"1210_CR20","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 2024; 403(10432): 1192\u20131204","journal-title":"Lancet"},{"issue":"10","key":"1210_CR21","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen CL, Haanen JB, Met \u00d6, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol 2022; 23(10): e450\u2013e458","journal-title":"Lancet Oncol"},{"issue":"4","key":"1210_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41588-023-01349-3","volume":"55","author":"NM Shah","year":"2023","unstructured":"Shah NM, Jang HJ, Liang Y, Maeng JH, Tzeng SC, Wu A, Basri NL, Qu X, Fan C, Li A, Katz B, Li D, Xing X, Evans BS, Wang T. Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements. Nat Genet 2023; 55(4): 631\u2013639","journal-title":"Nat Genet"},{"issue":"1","key":"1210_CR23","first-page":"100562","volume":"6","author":"AV Yaremenko","year":"2025","unstructured":"Yaremenko AV, Khan MM, Zhen X, Tang Y, Tao W. Clinical advances of mRNA vaccines for cancer immunotherapy. Med (N Y) 2025; 6(1): 100562","journal-title":"Med (N Y)"},{"issue":"7543","key":"1210_CR24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature14320","volume":"519","author":"DA Mitchell","year":"2015","unstructured":"Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519(7543): 366\u2013369","journal-title":"Nature"},{"issue":"610","key":"1210_CR25","doi-asserted-by":"publisher","first-page":"eabc7804","DOI":"10.1126\/scitranslmed.abc7804","volume":"13","author":"C Hotz","year":"2021","unstructured":"Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A, Hsu K, Bernardo M, Karik\u00f3 K, Kreiter S, Kuhn AN, Levit M, Malkova N, Masciari S, Pollard J, Qu H, Ryan S, Selmi A, Schlereth J, Singh K, Sun F, Tillmann B, Tolstykh T, Weber W, Wicke L, Witzel S, Yu Q, Zhang YA, Zheng G, Lager J, Nabel GJ, Sahin U, Wiederschain D. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med 2021; 13(610): eabc7804","journal-title":"Sci Transl Med"},{"issue":"22","key":"1210_CR26","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.1158\/1078-0432.CCR-21-0987","volume":"27","author":"A Porciuncula","year":"2021","unstructured":"Porciuncula A, Morgado M, Gupta R, Syrigos K, Meehan R, Zacharek SJ, Frederick JP, Schalper KA. Spatial mapping and immunomodulatory role of the OX40\/OX40L pathway in human non-small cell lung cancer. Clin Cancer Res 2021; 27(22): 6174\u20136183","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1210_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamaoncol.2024.5927","volume":"11","author":"K Ramalingam","year":"2025","unstructured":"Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, Hirst G, Rosenbluth J, Onishi N, Gibbs J, Hylton N, Borowsky AD, Campbell M, Esserman LJ. Intratumoral injection of mRNA-2752 and pembrolizumab for high-risk ductal carcinoma in situ: a phase 1 nonrandomized clinical trial. JAMA Oncol 2025; 11(3): 288\u2013292","journal-title":"JAMA Oncol"},{"issue":"23","key":"1210_CR28","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","volume":"26","author":"SL Hewitt","year":"2020","unstructured":"Hewitt SL, Bailey D, Zielinski J, Apte A, Musenge F, Karp R, Burke S, Garcon F, Mishra A, Gurumurthy S, Watkins A, Arnold K, Moynihan J, Clancy-Thompson E, Mulgrew K, Adjei G, Deschler K, Potz D, Moody G, Leinster DA, Novick S, Sulikowski M, Bagnall C, Martin P, Lapointe JM, Si H, Morehouse C, Sedic M, Wilkinson RW, Herbst R, Frederick JP, Luheshi N. Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment. Clin Cancer Res 2020; 26(23): 6284\u20136298","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1210_CR29","doi-asserted-by":"publisher","first-page":"e000329","DOI":"10.1136\/jitc-2019-000329","volume":"8","author":"B De Keersmaecker","year":"2020","unstructured":"De Keersmaecker B, Claerhout S, Carrasco J, Bar I, Corthals J, Wilgenhof S, Neyns B, Thielemans K. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. J Immunother Cancer 2020; 8(1): e000329","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1210_CR30","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/0008-5472.CAN-11-2957","volume":"72","author":"S Van Lint","year":"2012","unstructured":"Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, Pen J, Bonehill A, Heirman C, Breckpot K, Thielemans K. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012; 72(7): 1661\u20131671","journal-title":"Cancer Res"},{"issue":"7","key":"1210_CR31","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.ymthe.2021.03.002","volume":"29","author":"SW Tse","year":"2021","unstructured":"Tse SW, McKinney K, Walker W, Nguyen M, Iacovelli J, Small C, Hopson K, Zaks T, Huang E. mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response. Mol Ther 2021; 29(7): 2227\u20132238","journal-title":"Mol Ther"},{"issue":"7","key":"1210_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41565-022-01122-3","volume":"17","author":"D Zhang","year":"2022","unstructured":"Zhang D, Wang G, Yu X, Wei T, Farbiak L, Johnson LT, Taylor AM, Xu J, Hong Y, Zhu H, Siegwart DJ. Enhancing CRISPR\/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat Nanotechnol 2022; 17(7): 777\u2013787","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"1210_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol 2020; 15(4): 313\u2013320","journal-title":"Nat Nanotechnol"},{"issue":"8","key":"1210_CR34","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nat Rev Cancer 2023; 23(8): 526\u2013543","journal-title":"Nat Rev Cancer"},{"issue":"7643","key":"1210_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, G\u00f6nen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 2017; 543(7643): 113\u2013117","journal-title":"Nature"},{"issue":"1","key":"1210_CR36","doi-asserted-by":"publisher","first-page":"e20230036","DOI":"10.1002\/INMD.20230036","volume":"2","author":"K Xiao","year":"2024","unstructured":"Xiao K, Lai Y, Yuan W, Li S, Liu X, Xiao Z, Xiao H. mRNA - based chimeric antigen receptor T cell therapy: basic principles, recent advances and future directions. Interdiscip Med 2024; 2(1): e20230036","journal-title":"Interdiscip Med"},{"issue":"6747","key":"1210_CR37","doi-asserted-by":"publisher","first-page":"eadk3487","DOI":"10.1126\/science.adk3487","volume":"388","author":"ZA Ely","year":"2025","unstructured":"Ely ZA, Kulstad ZJ, Gunaydin G, Addepalli S, Verzani EK, Casarrubios M, Clauser KR, Wang X, Lippincott IE, Louvet C, Schmitt T, Kapner KS, Agus MP, Hennessey CJ, Cleary JM, Hadrup SR, Klaeger S, Su J, Jaeger AM, Wolpin BM, Raghavan S, Smith EL, Greenberg PD, Aguirre AJ, Abelin JG, Carr SA, Jacks T, Freed-Pastor WA. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science 2025; 388(6747): eadk3487","journal-title":"Science"},{"issue":"13","key":"1210_CR38","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1016\/j.cell.2025.03.047","volume":"188","author":"WJ Kim","year":"2025","unstructured":"Kim WJ, Crosse EI, De Neef E, Etxeberria I, Sabio EY, Wang E, Bewersdorf JP, Lin KT, Lu SX, Belleville A, Fox N, Castro C, Zhang P, Fujino T, Lewis J, Rahman J, Zhang B, Winick JH, Lewis AM, Stanley RF, DeWolf S, Urben BM, Takizawa M, Krause T, Molina H, Chaligne R, Koppikar P, Molldrem J, Gigoux M, Merghoub T, Daniyan A, Chandran SS, Greenbaum BD, Klebanoff CA, Bradley RK, Abdel-Wahab O. Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. Cell 2025; 188(13): 3422\u20133440.e24","journal-title":"Cell"},{"issue":"1","key":"1210_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","volume":"31","author":"J Lopez","year":"2025","unstructured":"Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, Balmanoukian AS, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher GA, Schmidt M, Schuler M, Sullivan RJ, Burris HA, Galvao V, Henick BS, Dirix L, Jaeger D, Ott PA, Wong KM, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner RS, Rittmeyer A, Laurie SA, Gort E, Aljumaily R, Melero I, Sabado RL, Rhee I, Mancuso MR, Muller L, Fine GD, Yadav M, Kim L, Leveque VJP, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao GK, Low DW, Petry C, Lo AA, Schartner JM, Delamarre L, Mellman I, L\u00f6wer M, M\u00fcller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, L\u00f6rks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kr\u00f6ner C, Tadmor AD, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn AN, Sahin U, T\u00fcreci \u00d6, Camidge DR. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med 2025; 31(1): 152\u2013164","journal-title":"Nat Med"},{"issue":"8056","key":"1210_CR40","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, Payne G, Lyudovyk O, Rojas LA, Pang N, Ohmoto A, Amisaki M, Zebboudj A, Odgerel Z, Bruno EM, Zhang SL, Cheng C, Elhanati Y, Derhovanessian E, Manning L, M\u00fcller F, Rhee I, Yadav M, Merghoub T, Wolchok JD, Basturk O, G\u00f6nen M, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D\u2019Angelica MI, Kingham TP, Soares KC, Jarnagin WR, Drebin J, O\u2019Reilly EM, Mellman I, Sahin U, T\u00fcreci \u00d6, Greenbaum BD, Balachandran VP. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 2025; 639(8056): 1042\u20131051","journal-title":"Nature"},{"issue":"12","key":"1210_CR41","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021; 6(12): 1078\u20131094","journal-title":"Nat Rev Mater"},{"issue":"13","key":"1210_CR42","doi-asserted-by":"publisher","first-page":"R526","DOI":"10.1016\/j.cub.2015.05.032","volume":"25","author":"M Cobb","year":"2015","unstructured":"Cobb M. Who discovered messenger RNA? Curr Biol 2015; 25(13): R526\u2013R532","journal-title":"Curr Biol"},{"issue":"5503","key":"1210_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/255033a0","volume":"255","author":"S Muthukrishnan","year":"1975","unstructured":"Muthukrishnan S, Both GW, Furuichi Y, Shatkin AJ. 5\u2032-Terminal 7-methylguanosine in eukaryotic mRNA is required for translation. Nature 1975; 255(5503): 33\u201337","journal-title":"Nature"},{"issue":"4949","key":"1210_CR44","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247(4949): 1465\u20131468","journal-title":"Science"},{"issue":"7","key":"1210_CR45","first-page":"1397","volume":"55","author":"RM Conry","year":"1995","unstructured":"Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, Benjamin R, Lu D, Curiel DT. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995; 55(7): 1397\u20131400","journal-title":"Cancer Res"},{"issue":"3","key":"1210_CR46","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1172\/JCI0214364","volume":"109","author":"A Heiser","year":"2002","unstructured":"Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109(3): 409\u2013417","journal-title":"J Clin Invest"},{"issue":"2","key":"1210_CR47","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3 K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23(2): 165\u2013175","journal-title":"Immunity"},{"issue":"16","key":"1210_CR48","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","volume":"86","author":"RW Malone","year":"1989","unstructured":"Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 1989; 86(16): 6077\u20136081","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"1210_CR49","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013; 8(11): 2281\u20132308","journal-title":"Nat Protoc"},{"issue":"7662","key":"1210_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, L\u00f6wer M, Bukur V, Tadmor AD, Luxemburger U, Schr\u00f6rs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, M\u00fcller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Br\u00fcck AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, H\u00f6ller C, Utikal J, Huber C, Loquai C, T\u00fcreci \u00d6. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547(7662): 222\u2013226","journal-title":"Nature"},{"issue":"5","key":"1210_CR51","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.ymthe.2022.02.016","volume":"30","author":"GT Szab\u00f3","year":"2022","unstructured":"Szab\u00f3 GT, Mahiny AJ, Vlatkovic I. COVID-19 mRNA vaccines: platforms and current developments. Mol Ther 2022; 30(5): 1850\u20131868","journal-title":"Mol Ther"},{"issue":"5","key":"1210_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, 0. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384(5): 403\u2013416","journal-title":"N Engl J Med"},{"issue":"19","key":"1210_CR53","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira EDJr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, P\u00e9rez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RWJr, Hammitt LL, T\u00fcreci \u00d6, Nell H, Schaefer A, \u00dcnal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, \u015eahin U, Gruber WC, Jansen KU. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 2021; 385(19): 1761\u20131773","journal-title":"N Engl J Med"},{"issue":"7823","key":"1210_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, Kranz LM, Diken M, Kreiter S, Haas H, Attig S, Rae R, Cuk K, Kemmer-Br\u00fcck A, Breitkreuz A, Tolliver C, Caspar J, Quinkhardt J, Hebich L, Stein M, Hohberger A, Vogler I, Liebig I, Renken S, Sikorski J, Leierer M, M\u00fcller V, Mitzel-Rink H, Miederer M, Huber C, Grabbe S, Utikal J, Pinter A, Kaufmann R, Hassel JC, Loquai C, T\u00fcreci \u00d6. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 2020; 585(7823): 107\u2013112","journal-title":"Nature"},{"key":"1210_CR55","doi-asserted-by":"publisher","first-page":"TPS9616","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9616","volume":"42","author":"JS Weber","year":"2024","unstructured":"Weber JS, Luke JJ, Carlino MS, Khattak MA, Meehan RS, Brown M, Zhang J, Krepler C, Duic JP, Long GV. INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II\u2013IV melanoma. J Clin Oncol 2024; 42(16 suppl): TPS9616","journal-title":"J Clin Oncol"},{"issue":"10","key":"1210_CR56","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","volume":"187","author":"HR Mendez-Gomez","year":"2024","unstructured":"Mendez-Gomez HR, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover BD, Xie C, Weidert F, Zhao C, Moor R, Liu R, Soni D, Ogando-Rivas E, Chardon-Robles J, McGuiness J, Zhang D, Chung MC, Marconi C, Michel S, Barpujari A, Jobin GW, Thomas N, Ma X, Campaneria Y, Grippin A, Karachi A, Li D, Sahay B, Elliott L, Foster TP, Coleman KE, Milner RJ, Sawyer WG, Ligon JA, Simon E, Cleaver B, Wynne K, Hodik M, Molinaro AM, Guan J, Kellish P, Doty A, Lee JH, Massini T, Kresak JL, Huang J, Hwang EI, Kline C, Carrera-Justiz S, Rahman M, Gatica S, Mueller S, Prados M, Ghiaseddin AP, Silver NL, Mitchell DA, Sayour EJ. RNA aggregates harness the danger response for potent cancer immunotherapy. Cell 2024; 187(10): 2521\u20132535.e21","journal-title":"Cell"},{"issue":"11","key":"1210_CR57","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, Heudobler D, Ferstl B, Klobuch S, Bokemeyer C, Desuki A, L\u00fcke F, Kutsch N, M\u00fcller F, Smit E, Hillemanns P, Karagiannis P, Wiegert E, He Y, Ho T, Kang-Fortner Q, Schlitter AM, Schulz-Eying C, Finlayson A, Flemmig C, K\u00fchlcke K, Preu\u00dfner L, Rengstl B, T\u00fcreci \u00d6, \u015eahin U. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med 2023; 29(11): 2844\u20132853","journal-title":"Nat Med"},{"key":"1210_CR58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","volume":"170","author":"J Kim","year":"2021","unstructured":"Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev 2021; 170: 83\u2013112","journal-title":"Adv Drug Deliv Rev"},{"issue":"686","key":"1210_CR59","doi-asserted-by":"publisher","first-page":"eabn3464","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"J Ramos da Silva","year":"2023","unstructured":"Ramos da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, Porchia BFMM, Moreno ACR, Aps LRMM, Venceslau-Carvalho AA, Tomb\u00e1cz I, Fotoran WL, Karik\u00f3 K, Lin PJC, Tam YK, de Oliveira Diniz M, Pardi N, de Souza Ferreira LC. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med 2023; 15(686): eabn3464","journal-title":"Sci Transl Med"},{"issue":"3","key":"1210_CR60","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA vaccine to balance innate\/adaptive immune response. Trends Mol Med 2020; 26(3): 311\u2013323","journal-title":"Trends Mol Med"},{"key":"1210_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2021.06.020","volume":"131","author":"M Gao","year":"2021","unstructured":"Gao M, Zhang Q, Feng XH, Liu J. Synthetic modified messenger RNA for therapeutic applications. Acta Biomater 2021; 131: 1\u201315","journal-title":"Acta Biomater"},{"issue":"16","key":"1210_CR62","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","volume":"44","author":"A Ramanathan","year":"2016","unstructured":"Ramanathan A, Robb GB, Chan SH. mRNA capping: biological functions and applications. Nucleic Acids Res 2016; 44(16): 7511\u20137526","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1210_CR63","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-biochem-013118-111042","volume":"88","author":"J Pelletier","year":"2019","unstructured":"Pelletier J, Sonenberg N. The organizing principles of eukaryotic ribosome recruitment. Annu Rev Biochem 2019; 88(1): 307\u2013335","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"1210_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.immuni.2015.06.015","volume":"43","author":"C Schuberth-Wagner","year":"2015","unstructured":"Schuberth-Wagner C, Ludwig J, Bruder AK, Herzner AM, Zillinger T, Goldeck M, Schmidt T, Schmid-Burgk JL, Kerber R, Wolter S, St\u00fcmpel JP, Roth A, Bartok E, Drosten C, Coch C, Hornung V, Barchet W, K\u00fcmmerer BM, Hartmann G, Schlee M. A conserved histidine in the RNA sensor RIG-I controls immune tolerance to N1-2\u2032O-methylated self RNA. Immunity 2015; 43(1): 41\u201351","journal-title":"Immunity"},{"issue":"11","key":"1210_CR65","doi-asserted-by":"publisher","first-page":"E2106","DOI":"10.1073\/pnas.1612444114","volume":"114","author":"YM Abbas","year":"2017","unstructured":"Abbas YM, Laudenbach BT, Mart\u00ednez-Montero S, Cencic R, Habjan M, Pichlmair A, Damha MJ, Pelletier J, Nagar B. Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2\u2032-O methylations. Proc Natl Acad Sci USA 2017; 114(11): E2106\u2013E2115","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"1210_CR66","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1021\/acs.accounts.3c00442","volume":"56","author":"M Warminski","year":"2023","unstructured":"Warminski M, Mamot A, Depaix A, Kowalska J, Jemielity J. Chemical modifications of mRNA ends for therapeutic applications. Acc Chem Res 2023; 56(20): 2814\u20132826","journal-title":"Acc Chem Res"},{"issue":"40","key":"1210_CR67","doi-asserted-by":"publisher","first-page":"2004452","DOI":"10.1002\/adma.202004452","volume":"32","author":"C Zeng","year":"2020","unstructured":"Zeng C, Hou X, Yan J, Zhang C, Li W, Zhao W, Du S, Dong Y. Leveraging mRNA sequences and nanoparticles to deliver SARS-CoV-2 antigens in vivo. Adv Mater 2020; 32(40): 2004452","journal-title":"Adv Mater"},{"issue":"9","key":"1210_CR68","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2015.103","volume":"23","author":"A Thess","year":"2015","unstructured":"Thess A, Grund S, Mui BL, Hope MJ, Baumhof P, Fotin-Mleczek M, Schlake T. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 2015; 23(9): 1456\u20131464","journal-title":"Mol Ther"},{"issue":"4","key":"1210_CR69","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.trecan.2019.02.011","volume":"5","author":"SL Schuster","year":"2019","unstructured":"Schuster SL, Hsieh AC. The untranslated regions of mRNAs in cancer. Trends Cancer 2019; 5(4): 245\u2013262","journal-title":"Trends Cancer"},{"issue":"11","key":"1210_CR70","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol 2022; 40(11): 1586\u20131600","journal-title":"Nat Biotechnol"},{"key":"1210_CR71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, Karik\u00f3 K. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Ther Nucleic Acids 2019; 15: 26\u201335","journal-title":"Mol Ther Nucleic Acids"},{"key":"1210_CR72","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","volume":"217","author":"O Andries","year":"2015","unstructured":"Andries O, McCafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada TN. (1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release 2015; 217: 337\u2013344","journal-title":"J Control Release"},{"key":"1210_CR73","doi-asserted-by":"publisher","first-page":"107534","DOI":"10.1016\/j.biotechadv.2020.107534","volume":"40","author":"Y Weng","year":"2020","unstructured":"Weng Y, Li C, Yang T, Hu B, Zhang M, Guo S, Xiao H, Liang XJ, Huang Y. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv 2020; 40: 107534","journal-title":"Biotechnol Adv"},{"issue":"14","key":"1210_CR74","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.3390\/ijms21145130","volume":"21","author":"K Lundstrom","year":"2020","unstructured":"Lundstrom K. Self-amplifying RNA viruses as RNA vaccines. Int J Mol Sci 2020; 21(14): 5130","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1210_CR75","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.ymthe.2024.07.003","volume":"32","author":"IC Casmil","year":"2024","unstructured":"Casmil IC, Blakney AK. Can self-amplifying RNA vaccines and viruses exchange genetic material? Mol Ther 2024; 32(8): 2437\u20132438","journal-title":"Mol Ther"},{"issue":"1","key":"1210_CR76","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","volume":"28","author":"T Beissert","year":"2020","unstructured":"Beissert T, Perkovic M, Vogel A, Erbar S, Walzer KC, Hempel T, Brill S, Haefner E, Becker R, T\u00fcreci \u00d6, Sahin U. A transamplifying RNA vaccine strategy for induction of potent protective immunity. Mol Ther 2020; 28(1): 119\u2013128","journal-title":"Mol Ther"},{"issue":"6","key":"1210_CR77","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.ymthe.2023.01.019","volume":"31","author":"M Perkovic","year":"2023","unstructured":"Perkovic M, Gawletta S, Hempel T, Brill S, Nett E, Sahin U, Beissert T. A trans-amplifying RNA simplified to essential elements is highly replicative and robustly immunogenic in mice. Mol Ther 2023; 31(6): 1636\u20131646","journal-title":"Mol Ther"},{"key":"1210_CR78","doi-asserted-by":"publisher","first-page":"113617","DOI":"10.1016\/j.jconrel.2025.113617","volume":"381","author":"Y Alshehry","year":"2025","unstructured":"Alshehry Y, Liu X, Zhang Y, Zhu G. Investigation of the impact of lipid nanoparticle compositions on the delivery and T cell response of circRNA vaccine. J Control Release 2025; 381: 113617","journal-title":"J Control Release"},{"issue":"11","key":"1210_CR79","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.molmed.2014.09.003","volume":"20","author":"VP Mauro","year":"2014","unstructured":"Mauro VP, Chappell SA. A critical analysis of codon optimization in human therapeutics. Trends Mol Med 2014; 20(11): 604\u2013613","journal-title":"Trends Mol Med"},{"issue":"5","key":"1210_CR80","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","volume":"7","author":"KD Nance","year":"2021","unstructured":"Nance KD, Meier JL. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent Sci 2021; 7(5): 748\u2013756","journal-title":"ACS Cent Sci"},{"issue":"7","key":"1210_CR81","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/molecules30071629","volume":"30","author":"J Camperi","year":"2025","unstructured":"Camperi J, Chatla K, Freund E, Galan C, Lippold S, Guilbaud A. Current analytical strategies for mRNA-based therapeutics. Molecules 2025; 30(7): 1629","journal-title":"Molecules"},{"issue":"1\u20132","key":"1210_CR82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/ten.tea.2017.0485","volume":"25","author":"Z Trepotec","year":"2019","unstructured":"Trepotec Z, Aneja MK, Geiger J, Hasenpusch G, Plank C, Rudolph C. Maximizing the translational yield of mRNA therapeutics by minimizing 5\u2032-UTRs. Tissue Eng Part A 2019; 25(1\u20132): 69\u201379","journal-title":"Tissue Eng Part A"},{"issue":"3","key":"1210_CR83","doi-asserted-by":"publisher","first-page":"101603","DOI":"10.1016\/j.jbc.2022.101603","volume":"298","author":"T Tominari","year":"2022","unstructured":"Tominari T, Akita M, Matsumoto C, Hirata M, Yoshinouchi S, Tanaka Y, Karouji K, Itoh Y, Maruyama T, Miyaura C, Numabe Y, Inada M. Endosomal TLR3 signaling in stromal osteoblasts induces prostaglandin E2-mediated inflammatory periodontal bone resorption. J Biol Chem 2022; 298(3): 101603","journal-title":"J Biol Chem"},{"key":"1210_CR84","doi-asserted-by":"crossref","unstructured":"Li Y, Wang F, Yang J, Han Z, Chen L, Jiang W, Zhou H, Li T, Tang Z, Deng J, He X, Zha G, Hu J, Hu Y, Wu L, Zhan C, Sun C, He Y, Xie Z. Deep generative optimization of mRNA codon sequences for enhanced protein production and therapeutic efficacy. bioRxiv 2024: 2024.09.06.611590","DOI":"10.1101\/2024.09.06.611590"},{"issue":"6","key":"1210_CR85","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","volume":"160","author":"V Presnyak","year":"2015","unstructured":"Presnyak V, Alhusaini N, Chen YH, Martin S, Morris N, Kline N, Olson S, Weinberg D, Baker KE, Graveley BR, Coller J. Codon optimality is a major determinant of mRNA stability. Cell 2015; 160(6): 1111\u20131124","journal-title":"Cell"},{"key":"1210_CR86","doi-asserted-by":"publisher","unstructured":"Zheng D, Persyn L, Wang J, Liu Y, Ulloa-Montoya F, Cenik C, Agarwal V. Predicting the translation efficiency of messenger RNA in mammalian cells. Nat Biotechnol 2025; [Epub ahead of print] doi: https:\/\/doi.org\/10.1038\/s41587-025-02712-x","DOI":"10.1038\/s41587-025-02712-x"},{"issue":"6","key":"1210_CR87","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/bioinformatics\/btv678","volume":"32","author":"G Terai","year":"2016","unstructured":"Terai G, Kamegai S, Asai K. CDSfold: an algorithm for designing a protein-coding sequence with the most stable secondary structure. Bioinformatics 2016; 32(6): 828\u2013834","journal-title":"Bioinformatics"},{"issue":"1","key":"1210_CR88","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41467-022-28776-w","volume":"13","author":"K Leppek","year":"2022","unstructured":"Leppek K, Byeon GW, Kladwang W, Wayment-Steele HK, Kerr CH, Xu AF, Kim DS, Topkar VV, Choe C, Rothschild D, Tiu GC, Wellington-Oguri R, Fujii K, Sharma E, Watkins AM, Nicol JJ, Romano J, Tunguz B, Diaz F, Cai H, Guo P, Wu J, Meng F, Shi S, Participants E, Dormitzer PR, Sol\u00f3rzano A, Barna M, Das R. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat Commun 2022; 13(1): 1536","journal-title":"Nat Commun"},{"key":"1210_CR89","unstructured":"Budzinska MA, Leonard TE, Chang RY, Chaudhary N, Cheetham SW, Mercer TR, Gunter HM. mRNArchitect: optimized design of mRNA sequences. bioRxiv 2024: 2024.12.03.626696"},{"issue":"W1","key":"1210_CR90","doi-asserted-by":"publisher","first-page":"W415","DOI":"10.1093\/nar\/gkaf410","volume":"53","author":"O Mo","year":"2025","unstructured":"Mo O, Zhang Z, Cheng X, Zhu L, Zhang K, Zhang N, Li J, Li H, Fan S, Li X, Hao P. mRNAdesigner: an integrated web server for optimizing mRNA design and protein translation in eukaryotes. Nucleic Acids Res 2025; 53(W1): W415\u2013W426","journal-title":"Nucleic Acids Res"},{"issue":"7978","key":"1210_CR91","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, Liu B, Ma X, Zhao F, Jiang H, Chen C, Shen H, Li H, Mathews DH, Zhang Y, Huang L. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 2023; 621(7978): 396\u2013403","journal-title":"Nature"},{"key":"1210_CR92","doi-asserted-by":"publisher","first-page":"1501010","DOI":"10.3389\/fcimb.2024.1501010","volume":"14","author":"S Imani","year":"2025","unstructured":"Imani S, Li X, Chen K, Maghsoudloo M, Jabbarzadeh Kaboli P, Hashemi M, Khoushab S, Li X. Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy. Front Cell Infect Microbiol 2025; 14: 1501010","journal-title":"Front Cell Infect Microbiol"},{"issue":"22","key":"1210_CR93","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.3390\/cancers16223884","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Singhal G, Kulkarni P, Horne D, Salgia R, Singhal SS. Artificial intelligence-driven computational approaches in the development of anticancer drugs. Cancers (Basel) 2024; 16(22): 3884","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1210_CR94","doi-asserted-by":"publisher","first-page":"bbad001","DOI":"10.1093\/bib\/bbad001","volume":"24","author":"H Gong","year":"2023","unstructured":"Gong H, Wen J, Luo R, Feng Y, Guo J, Fu H, Zhou X. Integrated mRNA sequence optimization using deep learning. Brief Bioinform 2023; 24(1): bbad001","journal-title":"Brief Bioinform"},{"issue":"7","key":"1210_CR95","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","volume":"25","author":"N Zaidi","year":"2025","unstructured":"Zaidi N, Jaffee EM, Yarchoan M. Recent advances in therapeutic cancer vaccines. Nat Rev Cancer 2025; 25(7): 517\u2013533","journal-title":"Nat Rev Cancer"},{"issue":"7607","key":"1210_CR96","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, H\u00fcsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, T\u00fcreci \u00d6, Sahin U. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534(7607): 396\u2013401","journal-title":"Nature"},{"issue":"7","key":"1210_CR97","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/gt.2011.17","volume":"18","author":"M Diken","year":"2011","unstructured":"Diken M, Kreiter S, Selmi A, Britten CM, Huber C, T\u00fcreci \u00d6, Sahin U. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 2011; 18(7): 702\u2013708","journal-title":"Gene Ther"},{"issue":"7963","key":"1210_CR98","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, M\u00fcller F, Rhee I, Yadav M, Dobrin A, Sadelain M, \u0141uksza M, Cohen N, Tang L, Basturk O, G\u00f6nen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D\u2019Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, T\u00fcreci \u00d6, Greenbaum BD, Jarnagin WR, Drebin J, O\u2019Reilly EM, Balachandran VP. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023; 618(7963): 144\u2013150","journal-title":"Nature"},{"issue":"10","key":"1210_CR99","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.4161\/hv.25181","volume":"9","author":"KJ Kallen","year":"2013","unstructured":"Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, Baumhof P, Scheel B, Koch SD, Fotin-Mleczek M. A novel, disruptive vaccination technology: self-adjuvanted RNActive(\u00ae) vaccines. Hum Vaccin Immunother 2013; 9(10): 2263\u20132276","journal-title":"Hum Vaccin Immunother"},{"issue":"Suppl 3","key":"1210_CR100","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/2051-1426-2-S3-P85","volume":"2","author":"SD Koch","year":"2014","unstructured":"Koch SD, Hong H, Feyerabend S, Retz M, Kuebler H, Heidenreich A, van Erps T, Schroeder A, Scheel B, Reus V, Kallen KJ, Fotin-Mleczek M, Gnad-Vogt U, Stenzl A. A randomized, double-blind, placebo-controlled, Phase I\/II trial of RNActive\u00ae-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part. J Immunother Cancer 2014; 2(Suppl 3): 85","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1210_CR101","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","volume":"7","author":"A Papachristofilou","year":"2019","unstructured":"Papachristofilou A, Hipp MM, Klinkhardt U, Fr\u00fch M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Gei\u00dfler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schr\u00f6der A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer 2019; 7(1): 38","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1210_CR102","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1186\/1471-2407-14-748","volume":"14","author":"M Sebastian","year":"2014","unstructured":"Sebastian M, Papachristofilou A, Weiss C, Fr\u00fch M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive\u00ae) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 2014; 14(1): 748","journal-title":"BMC Cancer"},{"key":"1210_CR103","doi-asserted-by":"publisher","first-page":"TPS9107","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9107","volume":"36","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Ramirez KA, Schwarzenberger P, Ricciardi T, Macri MJ, Ryan A, Venhaus RR. Phase 1\/2 study of mRNA vaccine therapy + durvalumab (durva) \u00b1 tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2018; 36(15 suppl): TPS9107","journal-title":"J Clin Oncol"},{"issue":"2","key":"1210_CR104","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41551-024-01208-4","volume":"9","author":"D Yin","year":"2025","unstructured":"Yin D, Zhong Y, Ling S, Lu S, Wang X, Jiang Z, Wang J, Dai Y, Tian X, Huang Q, Wang X, Chen J, Li Z, Li Y, Xu Z, Jiang H, Wu Y, Shi Y, Wang Q, Xu J, Hong W, Xue H, Yang H, Zhang Y, Da L, Han ZG, Tao SC, Dong R, Ying T, Hong J, Cai Y. Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat Biomed Eng 2025; 9(2): 185\u2013200","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"1210_CR105","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","volume":"5","author":"S Ling","year":"2021","unstructured":"Ling S, Yang S, Hu X, Yin D, Dai Y, Qian X, Wang D, Pan X, Hong J, Sun X, Yang H, Paludan SR, Cai Y. Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. Nat Biomed Eng 2021; 5(2): 144\u2013156","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"1210_CR106","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41565-024-01851-7","volume":"20","author":"S Ling","year":"2025","unstructured":"Ling S, Zhang X, Dai Y, Jiang Z, Zhou X, Lu S, Qian X, Liu J, Selfjord N, Satir TM, Lundin A, Touza JL, Firth M, Van Zuydam N, Bilican B, Akcakaya P, Hong J, Cai Y. Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington\u2019s disease gene therapy. Nat Nanotechnol 2025; 20(4): 543\u2013553","journal-title":"Nat Nanotechnol"},{"issue":"6557","key":"1210_CR107","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1126\/science.abg6155","volume":"373","author":"M Segel","year":"2021","unstructured":"Segel M, Lash B, Song J, Ladha A, Liu CC, Jin X, Mekhedov SL, Macrae RK, Koonin EV, Zhang F. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science 2021; 373(6557): 882\u2013889","journal-title":"Science"},{"issue":"16","key":"1210_CR108","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1002\/cncr.30696","volume":"123","author":"HJ Khoury","year":"2017","unstructured":"Khoury HJ, Collins RHJr, Blum W, Stiff PS, Elias L, Lebkowski JS, Reddy A, Nishimoto KP, Sen D, Wirth ED3rd, Case CC, DiPersio JF. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Cancer 2017; 123(16): 3061\u20133072","journal-title":"Cancer"},{"issue":"9","key":"1210_CR109","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/s41375-023-01980-3","volume":"37","author":"Y Fl\u00f8isand","year":"2023","unstructured":"Fl\u00f8isand Y, Remberger M, Bigalke I, Josefsen D, V\u00e5lerhaugen H, Inderberg EM, Olaussen RW, Gjertsen BT, Goedkoop R, Geiger C, Prinz PU, Schnorfeil FM, Pinkernell K, Schendel DJ, Kvalheim G. WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia 2023; 37(9): 1842\u20131849","journal-title":"Leukemia"},{"issue":"20","key":"1210_CR110","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-20-1082","volume":"26","author":"KA Batich","year":"2020","unstructured":"Batich KA, Mitchell DA, Healy P, Herndon JE2nd, Sampson JH. Once, twice, three times a finding: reproducibility of dendritic cell vaccine trials targeting cytomegalovirus in glioblastoma. Clin Cancer Res 2020; 26(20): 5297\u20135303","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1210_CR111","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/pros.24267","volume":"82","author":"AMA Tryggestad","year":"2022","unstructured":"Tryggestad AMA, Axcrona K, Axcrona U, Bigalke I, Brennhovd B, Inderberg EM, H\u00f8nn\u00e5shagen TK, Skoge LJ, Solum G, Saeb\u00f8e-Larssen S, Josefsen D, Olaussen RW, Aamdal S, Skotheim RI, Myklebust TA, Schendel DJ, Lilleby W, Dueland S, Kvalheim G. Long-term first-in-man phase I\/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy. Prostate 2022; 82(2): 245\u2013253","journal-title":"Prostate"},{"issue":"11","key":"1210_CR112","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","volume":"28","author":"X Huang","year":"2022","unstructured":"Huang X, Kong N, Zhang X, Cao Y, Langer R, Tao W. The landscape of mRNA nanomedicine. Nat Med 2022; 28(11): 2273\u20132287","journal-title":"Nat Med"},{"issue":"1","key":"1210_CR113","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","volume":"18","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Wei Y, Tian X, Wei X. Cancer vaccines: current status and future directions. J Hematol Oncol 2025; 18(1): 18","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1210_CR114","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 2021; 18(4): 215\u2013229","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1210_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","volume":"34","author":"M Fotin-Mleczek","year":"2011","unstructured":"Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojki\u0107-Zrna S, Probst J, Kallen KJ. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011; 34(1): 1\u201315","journal-title":"J Immunother"},{"issue":"5","key":"1210_CR116","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","volume":"32","author":"B Weide","year":"2009","unstructured":"Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C. Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients. J Immunother 2009; 32(5): 498\u2013507","journal-title":"J Immunother"},{"issue":"8","key":"1210_CR117","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","volume":"19","author":"CC Smith","year":"2019","unstructured":"Smith CC, Selitsky SR, Chai S, Armistead PM, Vincent BG, Serody JS. Alternative tumour-specific antigens. Nat Rev Cancer 2019; 19(8): 465\u2013478","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"1210_CR118","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters. Cell 2022; 185(15): 2770\u20132788","journal-title":"Cell"},{"issue":"9","key":"1210_CR119","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41422-024-00990-9","volume":"34","author":"X Wang","year":"2024","unstructured":"Wang X, Wang W, Zou S, Xu Z, Cao D, Zhang S, Wei M, Zhan Q, Wen C, Li F, Chen H, Fu D, Jiang L, Zhao M, Shen B. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors. Cell Res 2024; 34(9): 661\u2013664","journal-title":"Cell Res"},{"issue":"11","key":"1210_CR120","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD, Goff SL, McGowan CT, Seitter S, Shindorf ML, Parikh A, Chatani PD, Robbins PF, Rosenberg SA. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest 2020; 130(11): 5976\u20135988","journal-title":"J Clin Invest"},{"issue":"2","key":"1210_CR121","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Basturk O, VanWyk H, Tavares AM, Seenappa LM, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, O\u2019Reilly EM. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med 2024; 30(2): 531\u2013542","journal-title":"Nat Med"},{"issue":"523","key":"1210_CR122","doi-asserted-by":"publisher","first-page":"eaaw1565","DOI":"10.1126\/scitranslmed.aaw1565","volume":"11","author":"N Kong","year":"2019","unstructured":"Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi S, Ji X, Shajii A, Gan ST, Kim NY, Duda DG, Xie T, Farokhzad OC, Shi J. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci Transl Med 2019; 11(523): eaaw1565","journal-title":"Sci Transl Med"},{"issue":"10427","key":"1210_CR123","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024; 403(10427): 632\u2013644","journal-title":"Lancet"},{"issue":"11","key":"1210_CR124","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1158\/2159-8290.CD-24-1196","volume":"14","author":"P Berraondo","year":"2024","unstructured":"Berraondo P, Cuesta R, Sanmamed MF, Melero I. Immunogenicity and efficacy of personalized adjuvant mRNA cancer vaccines. Cancer Discov 2024; 14(11): 2021\u20132024","journal-title":"Cancer Discov"},{"issue":"11","key":"1210_CR125","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"JF Gainor","year":"2024","unstructured":"Gainor JF, Patel MR, Weber JS, Gutierrez M, Bauman JE, Clarke JM, Julian R, Scott AJ, Geiger JL, Kirtane K, Robert-Tissot C, Coder B, Tasneem M, Sun J, Zheng W, Gerbereux L, Laino A, Porichis F, Pollard JR, Hou P, Sehgal V, Chen X, Morrissey M, Daghestani HN, Feldman I, Srinivasan L, Frederick JP, Brown M, Aanur P, Meehan R, Burris HA3rd. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov 2024; 14(11): 2209\u20132223","journal-title":"Cancer Discov"},{"issue":"D1","key":"1210_CR126","doi-asserted-by":"publisher","first-page":"D1276","DOI":"10.1093\/nar\/gkad922","volume":"52","author":"H Kumar","year":"2024","unstructured":"Kumar H, Luo R, Wen J, Yang C, Zhou X, Kim P. FusionNeoAntigen: a resource of fusion gene-specific neoantigens. Nucleic Acids Res 2024; 52(D1): D1276\u2013D1288","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"1210_CR127","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1172\/JCI137723","volume":"130","author":"MA Biernacki","year":"2020","unstructured":"Biernacki MA, Foster KA, Woodward KB, Coon ME, Cummings C, Cunningham TM, Dossa RG, Brault M, Stokke J, Olsen TM, Gardner K, Estey E, Meshinchi S, Rongvaux A, Bleakley M. CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. J Clin Invest 2020; 130(10): 5127\u20135141","journal-title":"J Clin Invest"},{"key":"1210_CR128","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fimmu.2020.00121","volume":"11","author":"MA Biernacki","year":"2020","unstructured":"Biernacki MA, Bleakley M. Neoantigens in hematologic malignancies. Front Immunol 2020; 11: 121","journal-title":"Front Immunol"},{"issue":"10","key":"1210_CR129","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41375-025-02710-7","volume":"39","author":"R Tirtakusuma","year":"2025","unstructured":"Tirtakusuma R, Ghonim MA, Schattgen S, Muller B, Van de Velde LA, Khan TM, Crawford JC, Ma J, Abdelhamed S, Vegesana K, Awad W, Allen EK, Iacobucci I, Mullighan CG, Klco JM, Thomas PG. Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias. Leukemia 2025; 39(10): 2419\u20132431","journal-title":"Leukemia"},{"issue":"1","key":"1210_CR130","doi-asserted-by":"publisher","first-page":"16025","DOI":"10.1038\/sigtrans.2016.25","volume":"1","author":"H Tian","year":"2016","unstructured":"Tian H, Shi G, Wang Q, Li Y, Yang Q, Li C, Yang G, Wu M, Xie Q, Zhang S, Yang Y, Xiang R, Yu D, Wei Y, Deng H. A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. Signal Transduct Target Ther 2016; 1(1): 16025","journal-title":"Signal Transduct Target Ther"},{"issue":"8Supplement","key":"1210_CR131","doi-asserted-by":"publisher","first-page":"LB198","DOI":"10.1158\/1538-7445.AM2023-LB198","volume":"83","author":"O Bechter","year":"2023","unstructured":"Bechter O, Loquai C, Champiat S, Baurain JF, Grob JJ, Utikal J, Rottey S, Berrocal A, Hassel J, Arance A, Sanmamed MF, Boers-Sonderen M, Gastman B, Gebhardt C, Delafontaine B, Sahin U, T\u00fcreci \u00d6, Abbadessa G, Genova GD, Brueck P, Marpadga R, Lee H, Lebbe C. Abstract LB198: A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors. Cancer Res 2023; 83(8 Supplement): LB198 (-LB.)","journal-title":"Cancer Res"},{"issue":"6","key":"1210_CR132","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s00262-005-0064-z","volume":"55","author":"PR Hess","year":"2006","unstructured":"Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor\/self antigen. Cancer Immunol Immunother 2006; 55(6): 672\u2013683","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"1210_CR133","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.2025028597","volume":"146","author":"D Dutta","year":"2025","unstructured":"Dutta D, Liu J, Wen K, Ray A, Salatino A, Liu X, Gulla A, Hideshima T, Song Y, Anderson KC. A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma. Blood 2025; 146(19): 2322\u20132335","journal-title":"Blood"},{"issue":"9","key":"1210_CR134","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1021\/acsnano.4c14102","volume":"19","author":"X Xu","year":"2025","unstructured":"Xu X, Wang X, Liao YP, Luo L, Nel AE. Reprogramming the tolerogenic immune response against pancreatic cancer metastases by lipid nanoparticles delivering a STING agonist plus mutant KRAS mRNA. ACS Nano 2025; 19(9): 8579\u20138594","journal-title":"ACS Nano"},{"issue":"1","key":"1210_CR135","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1(1): 26\u201331","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"1210_CR136","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, Posey ADJr, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJ, Schuchter LM, Vonderheide RH, June CH. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol Res 2017; 5(12): 1152\u20131161","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1210_CR137","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun 2020; 11(1): 6080","journal-title":"Nat Commun"},{"issue":"6576","key":"1210_CR138","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, Mui BL, Albelda SM, Pur\u00e9 E, June CH, Aghajanian H, Weissman D, Parhiz H, Epstein JA. CAR T cells produced in vivo to treat cardiac injury. Science 2022; 375(6576): 91\u201396","journal-title":"Science"},{"issue":"6753","key":"1210_CR139","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, Wang A, Li JJ, Soldevila F, Chu DSH, Nguyen DP, Yong QC, Ross B, Nguyen M, Vestal J, Roberts S, Galvan D, Vega JB, Jhung D, Butcher M, Nguyen J, Zhang S, Fernandez C, Chen J, Herrera C, Kuo Y, Pica EM, Mondal G, Mammen AL, Scholler J, Tanis SP, Sievers SA, Frantz AM, Adams GB, Shawver L, Farzaneh-Far R, Rosenzweig M, Karmali PP, Bot AI, June CH, Aghajanian H. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 2025; 388(6753): 1311\u20131317","journal-title":"Science"},{"issue":"7976","key":"1210_CR140","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson JL, Juergens D, Bennett NR, Trippe BL, Yim J, Eisenach HE, Ahern W, Borst AJ, Ragotte RJ, Milles LF, Wicky BIM, Hanikel N, Pellock SJ, Courbet A, Sheffler W, Wang J, Venkatesh P, Sappington I, Torres SV, Lauko A, De Bortoli V, Mathieu E, Ovchinnikov S, Barzilay R, Jaakkola TS, DiMaio F, Baek M, Baker D. De novo design of protein structure and function with RFdiffusion. Nature 2023; 620(7976): 1089\u20131100","journal-title":"Nature"},{"issue":"6615","key":"1210_CR141","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","volume":"378","author":"J Dauparas","year":"2022","unstructured":"Dauparas J, Anishchenko I, Bennett N, Bai H, Ragotte RJ, Milles LF, Wicky BIM, Courbet A, de Haas RJ, Bethel N, Leung PJY, Huddy TF, Pellock S, Tischer D, Chan F, Koepnick B, Nguyen H, Kang A, Sankaran B, Bera AK, King NP, Baker D. Robust deep learning-based protein sequence design using ProteinMPNN. Science 2022; 378(6615): 49\u201356","journal-title":"Science"},{"issue":"7873","key":"1210_CR142","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, \u017d\u00eddek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli P, Hassabis D. Highly accurate protein structure prediction with AlphaFold. Nature 2021; 596(7873): 583\u2013589","journal-title":"Nature"},{"issue":"6758","key":"1210_CR143","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1126\/science.adv0185","volume":"389","author":"B Liu","year":"2025","unstructured":"Liu B, Greenwood NF, Bonzanini JE, Motmaen A, Meyerberg J, Dao T, Xiang X, Ault R, Sharp J, Wang C, Visani GM, Vafeados DK, Roullier N, Nourmohammad A, Scheinberg DA, Garcia KC, Baker D. Design of high-specificity binders for peptide-MHC-I complexes. Science 2025; 389(6758): 386\u2013391","journal-title":"Science"},{"issue":"6758","key":"1210_CR144","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1126\/science.adv0422","volume":"389","author":"KH Johansen","year":"2025","unstructured":"Johansen KH, Wolff DS, Scapolo B, Fern\u00e1ndez-Quintero ML, Risager Christensen C, Loeffler JR, Rivera-de-Torre E, Overath MD, Kj\u00e6rgaard Munk K, Morell O, Viuff MC, Lacunza I, Damm Englund AT, Due M, Gharpure A, Forli S, Rodriguez Pardo C, Tamhane T, Qingjie Andersen E, Haldrup Bj\u00f6rnsson K, Fernandes JS, Voss LF, Thumtecho S, Ward AB, Ormh\u00f8j M, Reker Hadrup S, Jenkins TP. De novo-designed pMHC binders facilitate T cell-mediated cytotoxicity toward cancer cells. Science 2025; 389(6758): 380\u2013385","journal-title":"Science"},{"issue":"6758","key":"1210_CR145","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1126\/science.adv3813","volume":"389","author":"KD Householder","year":"2025","unstructured":"Householder KD, Xiang X, Jude KM, Deng A, Obenaus M, Zhao Y, Wilson SC, Chen X, Wang N, Garcia KC. De novo design and structure of a peptide-centric TCR mimic binding module. Science 2025; 389(6758): 375\u2013379","journal-title":"Science"},{"key":"1210_CR146","doi-asserted-by":"publisher","first-page":"1294929","DOI":"10.3389\/fimmu.2023.1294929","volume":"14","author":"B Clemente","year":"2023","unstructured":"Clemente B, Denis M, Silveira CP, Schiavetti F, Brazzoli M, Stranges D. Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design. Front Immunol 2023; 14: 1294929","journal-title":"Front Immunol"},{"issue":"14","key":"1210_CR147","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.7150\/thno.93745","volume":"14","author":"L Huang","year":"2024","unstructured":"Huang L, Huang Z, Zhang Y, Lin C, Zhao Z, Li R, Saw PE, Xu X. Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy. Theranostics 2024; 14(14): 5528\u20135550","journal-title":"Theranostics"},{"issue":"26","key":"1210_CR148","doi-asserted-by":"publisher","first-page":"e2301606120","DOI":"10.1073\/pnas.2301606120","volume":"120","author":"E Ben-Akiva","year":"2023","unstructured":"Ben-Akiva E, Karlsson J, Hemmati S, Yu H, Tzeng SY, Pardoll DM, Green JJ. Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination. Proc Natl Acad Sci USA 2023; 120(26): e2301606120","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1210_CR149","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1038\/s41467-025-62878-5","volume":"16","author":"J Yang","year":"2025","unstructured":"Yang J, Wang C, Fu D, Ho LL, Galani K, Chen L, Gonzalez J, Fu J, Huang AY, Frederick DT, He L, Asnani M, Tacke R, Robitschek EJ, Yadav SK, Deng W, Burke KP, Sharova T, Sullivan RJ, Weiss S, Rai K, Liu D, Boland GM, Kellis M. Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma. Nat Commun 2025; 16(1): 8151","journal-title":"Nat Commun"},{"issue":"1","key":"1210_CR150","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12943-025-02400-z","volume":"24","author":"K Mandal","year":"2025","unstructured":"Mandal K, Barik GK, Santra MK. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions. Mol Cancer 2025; 24(1): 246","journal-title":"Mol Cancer"},{"issue":"1","key":"1210_CR151","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 2017; 18(1): 248\u2013262","journal-title":"Cell Rep"},{"issue":"6","key":"1210_CR152","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe\u2019er D, Allison JP. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 2017; 170(6): 1120\u20131133.e17","journal-title":"Cell"},{"issue":"1","key":"1210_CR153","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cell.2016.01.021","volume":"165","author":"R Basu","year":"2016","unstructured":"Basu R, Whitlock BM, Husson J, Le Floc\u2019h A, Jin W, Oyler-Yaniv A, Dotiwala F, Giannone G, Hivroz C, Biais N, Lieberman J, Kam LC, Huse M. Cytotoxic T cells use mechanical force to potentiate target cell killing. Cell 2016; 165(1): 100\u2013110","journal-title":"Cell"},{"issue":"13","key":"1210_CR154","doi-asserted-by":"publisher","first-page":"E2776","DOI":"10.1073\/pnas.1620498114","volume":"114","author":"GP Mognol","year":"2017","unstructured":"Mognol GP, Spreafico R, Wong V, Scott-Browne JP, Togher S, Hoffmann A, Hogan PG, Rao A, Trifari S. Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells. Proc Natl Acad Sci USA 2017; 114(13): E2776\u2013E2785","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1210_CR155","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol 2022; 22(4): 209\u2013223","journal-title":"Nat Rev Immunol"},{"issue":"7967","key":"1210_CR156","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, H\u00f6hn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfu\u00df S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine JC, Kastenm\u00fcller W, M\u00fcller AJ, T\u00fcting T. CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 2023; 618(7967): 1033\u20131040","journal-title":"Nature"},{"issue":"25","key":"1210_CR157","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","volume":"184","author":"C Cui","year":"2021","unstructured":"Cui C, Wang J, Fagerberg E, Chen PM, Connolly KA, Damo M, Cheung JF, Mao T, Askari AS, Chen S, Fitzgerald B, Foster GG, Eisenbarth SC, Zhao H, Craft J, Joshi NS. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 2021; 184(25): 6101\u20136118.e13","journal-title":"Cell"},{"issue":"6","key":"1210_CR158","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20171450","volume":"215","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, LaBranche CC, Montefiori DC, Lobby JL, Saunders KO, Liao HX, Korber BT, Sutherland LL, Scearce RM, Hraber PT, Tomb\u00e1cz I, Muramatsu H, Ni H, Balikov DA, Li C, Mui BL, Tam YK, Krammer F, Karik\u00f3 K, Polacino P, Eisenlohr LC, Madden TD, Hope MJ, Lewis MG, Lee KK, Hu SL, Hensley SE, Cancro MP, Haynes BF, Weissman D. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 2018; 215(6): 1571\u20131588","journal-title":"J Exp Med"},{"issue":"12","key":"1210_CR159","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"MG Alameh","year":"2021","unstructured":"Alameh MG, Tomb\u00e1cz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore JR, Gaudette BT, Soliman OY, Pine M, Hicks P, Manzoni TB, Knox JJ, Johnson JL, Laczk\u00f3 D, Muramatsu H, Davis B, Meng W, Rosenfeld AM, Strohmeier S, Lin PJC, Mui BL, Tam YK, Karik\u00f3 K, Jacquet A, Krammer F, Bates P, Cancro MP, Weissman D, Luning Prak ET, Allman D, Locci M, Pardi N. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 2021; 54(12): 2877\u20132892.e7","journal-title":"Immunity"},{"issue":"4","key":"1210_CR160","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.immuni.2018.08.012","volume":"49","author":"S Hong","year":"2018","unstructured":"Hong S, Zhang Z, Liu H, Tian M, Zhu X, Zhang Z, Wang W, Zhou X, Zhang F, Ge Q, Zhu B, Tang H, Hua Z, Hou B. B cells are the dominant antigen-presenting cells that activate naive CD4+ T cells upon immunization with a virus-derived nanoparticle antigen. Immunity 2018; 49(4): 695\u2013708.e4","journal-title":"Immunity"},{"issue":"6576","key":"1210_CR161","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science 2022; 375(6576): eabf9419","journal-title":"Science"},{"issue":"7850","key":"1210_CR162","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-03144-0","volume":"591","author":"S Biswas","year":"2021","unstructured":"Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 2021; 591(7850): 464\u2013470","journal-title":"Nature"},{"key":"1210_CR163","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2019.37.15_suppl.2641","volume":"37","author":"AMA Fernandez","year":"2019","unstructured":"Fernandez AMA, Baurain JF, Vulsteke C, Rutten A, Soria A, Carrasco J, Neyns B, Keersmaecker BD, Assche TV, Lindmark B. A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity. J Clin Oncol 2019; 37(15 suppl): 2641","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"1210_CR164","first-page":"A451","volume":"9","author":"M Linch","year":"2021","unstructured":"Linch M, Papai Z, Takacs I, Imedio ER, K\u00fchnle MC, Derhovanessian E, Vogler I, Renken S, Graham P, Sahin U, T\u00fcreci \u00d6. 421 A first-in-human (FIH) phase I\/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT.. J Immunother Cancer 2021; 9(Suppl 2): A451","journal-title":"J Immunother Cancer"},{"key":"1210_CR165","doi-asserted-by":"publisher","first-page":"S276","DOI":"10.1016\/j.annonc.2020.08.209","volume":"31","author":"M Schmidt","year":"2020","unstructured":"Schmidt M, Vogler I, Derhovanessian E, Omokoko T, Godehardt E, Attig S, Cortini A, Newrzela S, Gr\u00fctzner J, Bolte S, Langer D, Eichbaum M, Lindman H, Pascolo S, Schneeweiss A, Sj\u00f6blom T, T\u00fcreci \u00d6, Sahin U. 88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer. Ann Oncol 2020; 31: S276","journal-title":"Ann Oncol"},{"issue":"8","key":"1210_CR166","doi-asserted-by":"publisher","first-page":"962","DOI":"10.2174\/0115680096360059250131075456","volume":"25","author":"MS Hussain","year":"2025","unstructured":"Hussain MS, Sultana A, Bisht AS, Gupta G. Groundbreaking mRNA lung cancer vaccine trials: a new dawn in cancer treatment. Curr Cancer Drug Targets 2025; 25(8): 962\u2013967","journal-title":"Curr Cancer Drug Targets"},{"issue":"8","key":"1210_CR167","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41587-022-01247-9","volume":"40","author":"D Weber","year":"2022","unstructured":"Weber D, Ibn-Salem J, Sorn P, Suchan M, Holtstr\u00e4ter C, Lahrmann U, Vogler I, Schmoldt K, Lang F, Schr\u00f6rs B, L\u00f6wer M, Sahin U. Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens. Nat Biotechnol 2022; 40(8): 1276\u20131284","journal-title":"Nat Biotechnol"},{"key":"1210_CR168","doi-asserted-by":"publisher","first-page":"TPS3641","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3641","volume":"40","author":"S Kopetz","year":"2022","unstructured":"Kopetz S, Morris VK, Alonso-Ordu\u00f1a V, Garcia-Alfonso P, Reboredo M, Montes AF, Maurel J, Paez D, Reinacher-Schick AC, H\u00f6hler T, Carrasco J, Galligan BM, Manning L, Preu\u00dfner L, Tureci \u00d6, Sahin U. A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II\/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting. J Clin Oncol 2022; 40(16 suppl): TPS3641","journal-title":"J Clin Oncol"},{"issue":"1","key":"1210_CR169","doi-asserted-by":"publisher","first-page":"2255041","DOI":"10.1080\/2162402X.2023.2255041","volume":"12","author":"H B\u00e4hr-Mahmud","year":"2023","unstructured":"B\u00e4hr-Mahmud H, Ellinghaus U, Stadler CR, Fischer L, Lindemann C, Chaturvedi A, Diekmann J, W\u00f6ll S, Biermann I, Hebich B, Scharf C, Siefke M, Roth AS, Rao M, Brettschneider K, Ewen EM, \u015eahin U, T\u00fcreci \u00d6. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody. OncoImmunology 2023; 12(1): 2255041","journal-title":"OncoImmunology"},{"issue":"748","key":"1210_CR170","doi-asserted-by":"publisher","first-page":"eadl2720","DOI":"10.1126\/scitranslmed.adl2720","volume":"16","author":"CR Stadler","year":"2024","unstructured":"Stadler CR, Ellinghaus U, Fischer L, B\u00e4hr-Mahmud H, Rao M, Lindemann C, Chaturvedi A, Scharf C, Biermann I, Hebich B, Malz A, Beresin G, Falck G, H\u00e4cker A, Houben A, Erdeljan M, Wolf K, Kullmann M, Chang P, T\u00fcreci \u00d6, \u015eahin U. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6. Sci Transl Med 2024; 16(748): eadl2720","journal-title":"Sci Transl Med"},{"issue":"1","key":"1210_CR171","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12967-023-04433-8","volume":"21","author":"AG Simon","year":"2023","unstructured":"Simon AG, Lyu SI, Laible M, W\u00f6ll S, T\u00fcreci \u00d6, \u015eahin U, Alakus H, Fahrig L, Zander T, Buettner R, Bruns CJ, Schroeder W, Gebauer F, Quaas A. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis. J Transl Med 2023; 21(1): 552","journal-title":"J Transl Med"},{"issue":"1","key":"1210_CR172","doi-asserted-by":"publisher","first-page":"13474","DOI":"10.1038\/s41598-024-64116-2","volume":"14","author":"M Kraemer","year":"2024","unstructured":"Kraemer M, Zander T, Alakus H, Buettner R, Lyu SI, Simon AG, Schroeder W, Bruns CJ, Quaas A. Fetal gut cell-like differentiation in esophageal adenocarcinoma defines a rare tumor subtype with therapeutically relevant claudin-6 positivity and SWI\/SNF gene alteration. Sci Rep 2024; 14(1): 13474","journal-title":"Sci Rep"},{"issue":"2","key":"1210_CR173","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/CJI.0b013e31815ce501","volume":"31","author":"B Weide","year":"2008","unstructured":"Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee HG, Garbe C, Pascolo S. Results of the first phase I\/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008; 31(2): 180\u2013188","journal-title":"J Immunother"},{"key":"1210_CR174","doi-asserted-by":"publisher","first-page":"TPS2095","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2095","volume":"42","author":"G Tabatabai","year":"2024","unstructured":"Tabatabai G, Baumgarten LV, Bent MJVD, Burger MC, Freres P, Glas M, Hau P, Herrlinger U, Mildenberger I, Neyns B, Schafer HS, Seidel C, Galot R, Wick A, Falk MH. Chama LLdF, Kelemen P, Koch SD, Roche PR, Gnad-Vogt SU. Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma. J Clin Oncol 2024; 42(16 suppl): TPS2095","journal-title":"J Clin Oncol"},{"key":"1210_CR175","doi-asserted-by":"publisher","first-page":"TPS2676","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2676","volume":"41","author":"JD Powderly","year":"2023","unstructured":"Powderly JD, Sullivan RJ, Gutierrez M, Khattak A, Thomas SS, Jimeno A, Pascarella S, Zhu L, Morrissey M, Meehan RS, Barlaskar F, Brown M, Spigel DR. Phase 1\/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors. J Clin Oncol 2023; 41(16 suppl): TPS2676","journal-title":"J Clin Oncol"},{"key":"1210_CR176","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1016\/j.annonc.2024.08.729","volume":"35","author":"MA Khattak","year":"2024","unstructured":"Khattak MA, Sullivan RJ, Gutierrez M, Jimeno A, Thomas SS, Long GV, Kummar S, Daud A, Rohatgi A, Sweis RF, Bauman JE, Boni V, Parakh S, Daghestani HN, Xu J, Li Y, Morrissey M, Abadier M, Barlaskar F, Sarker D. 663P First-in-human, phase I\/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1\/IDO1 antigen-specific therapy, in advanced\/refractory solid tumors. Ann Oncol 2024; 35: S521\u2013S522","journal-title":"Ann Oncol"},{"key":"1210_CR177","doi-asserted-by":"publisher","first-page":"TPS8116","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8116","volume":"42","author":"JM Lee","year":"2024","unstructured":"Lee JM, Spicer J, Nair S, Khattak A, Brown M, Meehan RS. Shariati M, Deng X, Samkari A, Chaft JE, Shariati NM, Deng X, Samkari A, Chaft JE. The phase 3 INTerpath-002 study design: individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non\u2013small-cell lung cancer (NSCLC). J Clin Oncol 2024; 42(16 suppl): TPS8116","journal-title":"J Clin Oncol"},{"key":"1210_CR178","doi-asserted-by":"publisher","first-page":"TPS3635","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3635","volume":"40","author":"JR Hecht","year":"2022","unstructured":"Hecht JR, Shergill A, Goldstein MG, Fang B, Cho MT, Lenz HJ, Berim LD, Oberstein PE, Safyan RA, Sawhney V, Soares HP, Spigel DR, Spira AI, Ferguson AR, Chauder B, Starodub A. Phase 2\/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE). J Clin Oncol 2022; 40(16 suppl): TPS3635","journal-title":"J Clin Oncol"},{"issue":"8","key":"1210_CR179","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, Gitlin L, Kraemer LD, Kounlavouth S, Yang A, Smith L, Schenk D, Skoberne M, Taquechel K, Marrali M, Jaroslavsky JR, Nganje CN, Maloney E, Zhou R, Navarro-Gomez D, Greene AC, Grotenbreg G, Greer R, Blair W, Cao MD, Chan S, Bae K, Spira AI, Roychowdhury S, Carbone DP, Henick BS, Drake CG, Solomon BJ, Ahn DH, Mahipal A, Maron SB, Johnson B, Rousseau R, Yelensky R, Liao CY, Catenacci DVT, Allen A, Ferguson AR, Jooss K. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med 2022; 28(8): 1619\u20131629","journal-title":"Nat Med"},{"issue":"4","key":"1210_CR180","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, Liao CY, Mahipal A, Shergill A, Spira AI, Goldman JW, Scallan CD, Schenk D, Palmer CD, Davis MJ, Kounlavouth S, Kemp L, Yang A, Li YJ, Likes M, Shen A, Boucher GR, Egorova M, Veres RL, Espinosa JA, Jaroslavsky JR, Kraemer Tardif LD, Acrebuche L, Puccia C, Sousa L, Zhou R, Bae K, Hecht JR, Carbone DP, Johnson B, Allen A, Ferguson AR, Jooss K. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med 2024; 30(4): 1013\u20131022","journal-title":"Nat Med"},{"issue":"7","key":"1210_CR181","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/d41573-024-00098-0","volume":"23","author":"MT Villanueva","year":"2024","unstructured":"Villanueva MT. RNA delivery heats up cold tumours. Nat Rev Drug Discov 2024; 23(7): 497","journal-title":"Nat Rev Drug Discov"},{"key":"1210_CR182","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.2024.42.23_suppl.139","volume":"42","author":"X Peng","year":"2024","unstructured":"Peng X, He X, Zhang W, Huang H, Li X, Chen J, Wei Y, Song X. Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: results from an investigator-initiated trial. J Clin Oncol 2024; 42(23 suppl): 139","journal-title":"J Clin Oncol"},{"issue":"8Supplement","key":"1210_CR183","doi-asserted-by":"publisher","first-page":"CT004","DOI":"10.1158\/1538-7445.AM2023-CT004","volume":"83","author":"E Casta\u00f1\u00f3n","year":"2023","unstructured":"Casta\u00f1\u00f3n E, Zamarin D, Carneiro BA, Marron T, Patel SP, Subbiah V, Mehmi I, Oberoi HK, El-Khoueiry A, Ridgway B, Elgeioushi N, Durham NM, Jennings E, Abadier M, Fraenkel PG, Azaro A, Hamid O. Abstract CT004: Intratumoral (IT) MEDI1191 + durvalumab (D): update on the first-in-human study in advanced solid tumors. Cancer Res 2023; 83(8 Supplement): CT004","journal-title":"Cancer Res"},{"issue":"6Supplement","key":"1210_CR184","doi-asserted-by":"publisher","first-page":"6552","DOI":"10.1158\/1538-7445.AM2024-6552","volume":"84","author":"M Abadier","year":"2024","unstructured":"Abadier M, Sullivan RJ, Chow J, Sehgal V, Sweis RF, Daud A, Shapira-Frommer R, Perets R, Kummar S, McKean M, Geva R, Patel MR, Khattak A, Fernandez-Pe\u00f1as P, Zacharek S, Wahl N, Walker RM, Van L, Aanur P, Ward J, Do KT, Long GV. Abstract 6552: Intratumoral (ITu) delivery of mRNA-2752 encoding human OX40L\/IL-23\/IL-36\u03b3 in combination with durvalumab induces an immunostimulatory effect within the tumor microenvironment (TME) of patients with advanced solid tumors. Cancer Res 2024; 84(6 Supplement): 6552","journal-title":"Cancer Res"},{"issue":"31","key":"1210_CR185","doi-asserted-by":"publisher","first-page":"13824","DOI":"10.1073\/pnas.1008051107","volume":"107","author":"VF Van Tendeloo","year":"2010","unstructured":"Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, Stein B, Smits EL, Schroyens WA, Gadisseur AP, Vrelust I, Jorens PG, Goossens H, de Vries IJ, Price DA, Oji Y, Oka Y, Sugiyama H, Berneman ZN. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms\u2019 tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107(31): 13824\u201313829","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"1210_CR186","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","volume":"130","author":"S Anguille","year":"2017","unstructured":"Anguille S, Van de Velde AL, Smits EL, Van Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van Driessche A, Vandenbosch I, Verlinden A, Gadisseur AP, Schroyens WA, Muylle L, Vermeulen K, Maes MB, Deiteren K, Malfait R, Gostick E, Lammens M, Couttenye MM, Jorens P, Goossens H, Price DA, Ladell K, Oka Y, Fujiki F, Oji Y, Sugiyama H, Berneman ZN. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood 2017; 130(15): 1713\u20131721","journal-title":"Blood"},{"issue":"12","key":"1210_CR187","first-page":"5091","volume":"30","author":"WJ Lesterhuis","year":"2010","unstructured":"Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, Scharenborg NM, Van De Rakt M, Hesselink EJ, Figdor CG, Adema GJ, Punt CJ. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 2010; 30(12): 5091\u20135097","journal-title":"Anticancer Res"},{"issue":"3","key":"1210_CR188","doi-asserted-by":"publisher","first-page":"e077613","DOI":"10.1136\/bmjopen-2023-077613","volume":"14","author":"T Van Genechten","year":"2024","unstructured":"Van Genechten T, De Laere M, Van den Bossche J, Stein B, De Rycke K, Deschepper C, Hazes K, Peeters R, Couttenye MM, Van De Walle K, Roelant E, Maes S, Vanden Bossche S, Dekeyzer S, Huizing M, Caluwaert K, Nijs G, Cools N, Verlooy J, Norga K, Verhulst S, Anguille S, Berneman Z, Lion E. Adjuvant Wilms\u2019 tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I\/II clinical trial in Belgium. BMJ Open 2024; 14(3): e077613","journal-title":"BMJ Open"},{"issue":"8","key":"1210_CR189","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1158\/1078-0432.CCR-16-2057","volume":"23","author":"KA Batich","year":"2017","unstructured":"Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE2nd, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, Mitchell DA, Sampson JH. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res 2017; 23(8): 1898\u20131909","journal-title":"Clin Cancer Res"},{"issue":"Supplement_7","key":"1210_CR190","doi-asserted-by":"publisher","first-page":"vii61","DOI":"10.1093\/neuonc\/noac209.239","volume":"24","author":"M Rahman","year":"2022","unstructured":"Rahman M, Ghiaseddin A, Deleyrolle P, Peters KB, Archer G, Sampson J, Mitchell D. CTIM-07. PHASE II RANDOMIZED, BLINDED, PLACEBO-CONTROLLED TRIAL TESTING PP65 CMV MRNA DENDRITIC CELL VACCINE AND TETANUS-DIPHTHERIA TOXOID FOR NEWLY DIAGNOSED GBM (ATTAC II, NCT02465268). Neuro-oncol 2022; 24(Supplement_7): vii61","journal-title":"Neuro-oncol"},{"key":"1210_CR191","doi-asserted-by":"publisher","first-page":"e13518","DOI":"10.1200\/JCO.2016.34.15_suppl.e13518","volume":"34","author":"G Vlahovic","year":"2016","unstructured":"Vlahovic G, Archer GE, Reap E, Desjardins A, Peters KB, Randazzo D, Healy P, Herndon JE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM). J Clin Oncol 2016; 34(15 suppl): e13518","journal-title":"J Clin Oncol"},{"issue":"9","key":"1210_CR192","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00262-013-1453-3","volume":"62","author":"EO Vik-Mo","year":"2013","unstructured":"Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-T\u00f8nnesen P, Suso EM, S\u00e6b\u00f8e-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62(9): 1499\u20131509","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"1210_CR193","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/neuonc\/noaa170","volume":"22","author":"K Woroniecka","year":"2020","unstructured":"Woroniecka K, Fecci PE. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro-oncol 2020; 22(9): 1233\u20131234","journal-title":"Neuro-oncol"},{"issue":"9","key":"1210_CR194","first-page":"2127","volume":"63","author":"Z Su","year":"2003","unstructured":"Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63(9): 2127\u20132133","journal-title":"Cancer Res"},{"issue":"9","key":"1210_CR195","doi-asserted-by":"publisher","first-page":"e1207842","DOI":"10.1080\/2162402X.2016.1207842","volume":"5","author":"TH Borch","year":"2016","unstructured":"Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met \u00d6, Hansen M, Andersen MH, Thor Straten P, Svane IM. mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. OncoImmunology 2016; 5(9): e1207842","journal-title":"OncoImmunology"},{"issue":"1","key":"1210_CR196","doi-asserted-by":"publisher","first-page":"e1372081","DOI":"10.1080\/2162402X.2017.1372081","volume":"7","author":"DJ Chung","year":"2018","unstructured":"Chung DJ, Carvajal RD, Postow MA, Sharma S, Pronschinske KB, Shyer JA, Singh-Kandah S, Dickson MA, D\u2019Angelo SP, Wolchok JD, Young JW. Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: results of a phase I vaccine trial. OncoImmunology 2018; 7(1): e1372081","journal-title":"OncoImmunology"},{"key":"1210_CR197","doi-asserted-by":"publisher","first-page":"785231","DOI":"10.3389\/fimmu.2022.785231","volume":"13","author":"EAT Koch","year":"2022","unstructured":"Koch EAT, Schaft N, Kummer M, Berking C, Schuler G, Hasumi K, D\u00f6rrie J, Schuler-Thurner B. A one-armed phase I dose escalation trial design: personalized vaccination with IKK\u03b2-matured, RNA-loaded dendritic cells for metastatic uveal melanoma. Front Immunol 2022; 13: 785231","journal-title":"Front Immunol"},{"issue":"7","key":"1210_CR198","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/1758834017712630","volume":"9","author":"KF Gerer","year":"2017","unstructured":"Gerer KF, Erdmann M, Hadrup SR, Lyngaa R, Martin LM, Voll RE, Schuler-Thurner B, Schuler G, Schaft N, Hoyer S, D\u00f6rrie J. Preclinical evaluation of NF-\u03baB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination. Ther Adv Med Oncol 2017; 9(7): 451\u2013464","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"1210_CR199","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00347-015-0162-z","volume":"112","author":"B Schuler-Thurner","year":"2015","unstructured":"Schuler-Thurner B, Bartz-Schmidt KU, Bornfeld N, Cursiefen C, Fuisting B, Grisanti S, Heindl LM, Holbach L, Keser\u00fc M, Knorr H, Koch K, Kruse F, Meiller R, Metz C, Meyer-ter-Vehn T, Much M, Reinsberg M, Schliep S, Seitz B, Schuler G, S\u00fcsskind D, Viestenz A, Wagenfeld L, Zeschnigk M. Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma. Ophthalmologe 2015; 112(12): 1017\u20131021","journal-title":"Ophthalmologe"},{"issue":"7","key":"1210_CR200","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1172\/JCI67544","volume":"123","author":"J Dannull","year":"2013","unstructured":"Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, De Rosa N, Pickett N, Mosca PJ, Burchette J, Selim MA, Mitchell DA, Sampson J, Tyler DS, Pruitt SK. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 2013; 123(7): 3135\u20133145","journal-title":"J Clin Invest"},{"issue":"40","key":"1210_CR201","doi-asserted-by":"publisher","first-page":"67439","DOI":"10.18632\/oncotarget.18698","volume":"8","author":"SI Buschow","year":"2017","unstructured":"Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG. Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1\/Raf kinase inhibitory protein. Oncotarget 2017; 8(40): 67439\u201367456","journal-title":"Oncotarget"},{"issue":"5","key":"1210_CR202","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ajo.2014.07.014","volume":"158","author":"KF Bol","year":"2014","unstructured":"Bol KF, Mensink HW, Aarntzen EH, Schreibelt G, Keunen JE, Coulie PG, de Klein A, Punt CJ, Paridaens D, Figdor CG, de Vries IJ. Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. Am J Ophthalmol 2014; 158(5): 939\u2013947","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1210_CR203","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/bloodadvances.2021005941","volume":"6","author":"DJ Chung","year":"2022","unstructured":"Chung DJ, Sharma S, Rangesa M, DeWolf S, Elhanati Y, Perica K, Young JW. Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant. Blood Adv 2022; 6(5): 1547\u20131558","journal-title":"Blood Adv"},{"issue":"7","key":"1210_CR204","doi-asserted-by":"publisher","first-page":"e0307204","DOI":"10.1371\/journal.pone.0307204","volume":"19","author":"J Van den Bossche","year":"2024","unstructured":"Van den Bossche J, De Laere M, Deschepper K, Germonpr\u00e9 P, Valcke Y, Lamont J, Stein B, Van Camp K, Germonpr\u00e9 C, Nijs G, Roelant E, Anguille S, Lion E, Berneman Z. Integration of the PD-L1 inhibitor atezolizumab and WT1\/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study. PLoS One 2024; 19(7): e0307204","journal-title":"PLoS One"},{"issue":"16supplement","key":"1210_CR205","doi-asserted-by":"publisher","first-page":"S41.004","DOI":"10.1212\/WNL.88.16_supplement.S41.004","volume":"88","author":"A Dunn-Pirio","year":"2017","unstructured":"Dunn-Pirio A, Peters K, DesJardins A, Randazzo D, Friedman H, Healy P, Herndon J II, Reap E, Archer G, Li QJ, Sampson J, Vlahovic G. Tumor stem cell RNA-loaded dendritic cell vaccine for recurrent glioblastoma: a phase 1 trial (S41.004). Neurology 2017; 88(16 supplement): S41.004","journal-title":"Neurology"},{"key":"1210_CR206","doi-asserted-by":"publisher","first-page":"e14513","DOI":"10.1200\/JCO.2024.42.16_suppl.e14513","volume":"42","author":"P Liang","year":"2024","unstructured":"Liang P, Yu J, Wang L, Chen ST, Dong G, Hou QD, Zhang J, Cheng Z, Han ZY, Liu FY, Yu XL. A first-in-human study to evaluate a personalized neoantigen-based mRNA-loaded dendritic cell vaccine, in combination with ablation, in patients with hepatocellular carcinoma. J Clin Oncol 2024; 42(16 suppl): e14513","journal-title":"J Clin Oncol"},{"issue":"26","key":"1210_CR207","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1200\/JCO.23.02585","volume":"42","author":"FR van\u2019t Land","year":"2024","unstructured":"van\u2019t Land FR, Willemsen M, Bezemer K, van der Burg SH, van den Bosch TPP, Doukas M, Fellah A, Kolijn PM, Langerak AW, Moskie M, van der Oost E, Rozendaal NEM, Baart SJ, Aerts JGJV, van Eijck CHJ. Dendritic cell-based immunotherapy in patients with resected pancreatic cancer. J Clin Oncol 2024; 42(26): 3083\u20133093","journal-title":"J Clin Oncol"},{"issue":"5","key":"1210_CR208","first-page":"e83607","volume":"17","author":"K Liu","year":"2025","unstructured":"Liu K, Nagai H, Kanai N, Yamahara K. Complete response in recurrent end-stage pancreatic cancer after combined immune cell therapy of \u03b1-galactosylceramide dendritic cell vaccine therapy, Wilms\u2019 tumor 1 dendritic cell vaccine and natural killer cell therapy. Cureus 2025; 17(5): e83607","journal-title":"Cureus"},{"issue":"6","key":"1210_CR209","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.4049\/jimmunol.174.6.3798","volume":"174","author":"Z Su","year":"2005","unstructured":"Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, Vieweg J. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174(6): 3798\u20133807","journal-title":"J Immunol"},{"issue":"4","key":"1210_CR210","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jcyt.2017.01.007","volume":"19","author":"P Kongsted","year":"2017","unstructured":"Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met \u00d6, Hansen M, Lindberg H, Sengel\u00f8v L, Svane IM. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: a randomized phase II study. Cytotherapy 2017; 19(4): 500\u2013513","journal-title":"Cytotherapy"},{"issue":"5","key":"1210_CR211","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, 0. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411\u2013422","journal-title":"N Engl J Med"},{"issue":"6","key":"1210_CR212","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, Hovestadt V, WadsworthIi MH, Hughes TK, Griffin GK, Battaglia S, Verga JA, Stephansky J, Pastika TJ, Lombardi Story J, Pinkus GS, Pozdnyakova O, Galinsky I, Stone RM, Graubert TA, Shalek AK, Aster JC, Lane AA, Bernstein BE. Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell 2019; 176(6): 1265\u20131281.e24","journal-title":"Cell"},{"issue":"2","key":"1210_CR213","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11684-023-1022-x","volume":"18","author":"N Qiao","year":"2024","unstructured":"Qiao N, Lyu Y, Liu F, Zhang Y, Ma X, Lin X, Wang J, Xie Y, Zhang R, Qiao J, Zhu H, Chen L, Fang H, Yin T, Chen Z, Tian Q, Chen S. Cross-sectional network analysis of plasma proteins\/metabolites correlated with pathogenesis and therapeutic response in acute promyelocytic leukemia. Front Med 2024; 18(2): 327\u2013343","journal-title":"Front Med"},{"issue":"5","key":"1210_CR214","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.20.00475","volume":"39","author":"S Khaldoyanidi","year":"2021","unstructured":"Khaldoyanidi S, Nagorsen D, Stein A, Ossenkoppele G, Subklewe M. Immune biology of acute myeloid leukemia: implications for immunotherapy. J Clin Oncol 2021; 39(5): 419\u2013432","journal-title":"J Clin Oncol"},{"issue":"18","key":"1210_CR215","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen X, Lu Q, Zhou H, Liu J, Nadorp B, Lasry A, Sun Z, Lai B, Rona G, Zhang J, Cammer M, Wang K, Al-Santli W, Ciantra Z, Guo Q, You J, Sengupta D, Boukhris A, Zhang H, Liu C, Cresswell P, Dahia PLM, Pagano M, Aifantis I, Wang J. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 2023; 186(18): 3903\u20133920.e21","journal-title":"Cell"},{"key":"1210_CR216","doi-asserted-by":"publisher","first-page":"217427","DOI":"10.1016\/j.canlet.2024.217427","volume":"611","author":"P Jin","year":"2025","unstructured":"Jin P, Shen J, Zhao M, Yu J, Jin W, Jiang G, Li Z, He M, Liu X, Wu S, Dong F, Cao Y, Zhu H, Li X, Wang X, Zhang Y, Jin Z, Li J, Wang K. Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy. Cancer Lett 2025; 611: 217427","journal-title":"Cancer Lett"},{"key":"1210_CR217","doi-asserted-by":"publisher","first-page":"S600","DOI":"10.1016\/j.annonc.2024.08.860","volume":"35","author":"Y Song","year":"2024","unstructured":"Song Y, Zhou K, Hou S, Zhang Y, Li F, Yang W, Yi T, Lin N, Liu X, Meng W, Wang Z, Lu Q, Tian W, Zhu J. Efficacy and safety results from the phase II study of Timdarpacept in combination with tislelizumab, in prior anti-PD-1 failed classical Hodgkin lymphoma. Ann Oncol 2024; 35: S600\u2013S1","journal-title":"Ann Oncol"},{"key":"1210_CR218","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1200\/JCO.2020.38.15_suppl.3092","volume":"38","author":"MR Patel","year":"2020","unstructured":"Patel MR, Bauer TM, Jimeno A, Wang D, LoRusso P, Do KT, Stemmer SM, Maurice-Dror C, Geva R, Zacharek S, Laino AS, Sun J, Frederick J, Zhou H, Randolph W, Cohen PS, Meehan RS, Sullivan RJ. A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral (iTu) injection alone and in combination with durvalumab. J Clin Oncol 2020; 38(15 suppl): 3092","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"1210_CR219","first-page":"A569","volume":"9","author":"M Patel","year":"2021","unstructured":"Patel M, Jimeno A, Wang D, Stemmer S, Bauer T, Sweis R, Geva R, Kummar S, Reagan P, Perets R, LoRusso P, Gupta S, Zacharek S, Laino A, Milberg O, Frederick J, Chen S, Pascarella S, Randolph W, Aanur P, Johansen L, Do K, Meehan R, Sullivan R. 539 Phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L\/IL-23\/IL-36\u03b3, for intratumoral (ITu) injection +\/\u2212 durvalumab in advanced solid tumors and lymphoma. J Immunother Cancer 2021; 9(Suppl 2): A569","journal-title":"J Immunother Cancer"},{"key":"1210_CR220","doi-asserted-by":"publisher","first-page":"TPS7580","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7580","volume":"40","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Tees MT, Li A, Truppel-Hartmann A, Flinn IW. CRC-403: a phase 1\/2 study of bbT369, a dual targeting CAR T-cell drug product with a gene edit, in relapsed and\/or refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 2022; 40(16 suppl): TPS7580","journal-title":"J Clin Oncol"},{"issue":"10500","key":"1210_CR221","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu J, Liu L, Parone P, Xie W, Sun C, Chen Z, Zhang J, Li C, Hu Y, Mei H. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 2025; 406(10500): 228\u2013231","journal-title":"Lancet"},{"key":"1210_CR222","doi-asserted-by":"publisher","first-page":"1482715","DOI":"10.3389\/fimmu.2024.1482715","volume":"15","author":"JS Heitmann","year":"2024","unstructured":"Heitmann JS, Jung S, Wacker M, Maringer Y, Nelde A, Bauer J, Denk M, Hoenisch-Gravel N, Richter M, Oezbek MT, Dubbelaar ML, Bilich T, Pumptow M, Martus P, Illerhaus G, Denzlinger C, Steinbach F, Aulitzky WE, M\u00fcller MR, D\u00f6rfel D, Rammensee HG, Salih HR, Walz JS. Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients. Front Immunol 2024; 15: 1482715","journal-title":"Front Immunol"},{"issue":"5","key":"1210_CR223","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/2159-8290.CD-24-0934","volume":"15","author":"M Saxena","year":"2025","unstructured":"Saxena M, Marron TU, Kodysh J, Finnigan JPJr, Onkar S, Kaminska A, Tuballes K, Guo R, Sabado RL, Meseck M, O\u2019Donnell TJ, Sebra RP, Parekh S, Galsky MD, Blasquez A, Gimenez G, Bicak M, Cimen Bozkus C, Delbeau-Zagelbaum D, Rodriguez D, Acuna-Villaorduna A, Misiukiewicz KJ, Posner MR, Miles BA, Irie HY, Tiersten A, Doroshow DB, Wolf A, Mandeli J, Brody R, Salazar AM, Gnjatic S, Hammerbacher J, Schadt E, Friedlander P, Rubinsteyn A, Bhardwaj N. PGV001, a multi-peptide personalized neoantigen vaccine platform: phase i study in patients with solid and hematologic malignancies in the adjuvant setting. Cancer Discov 2025; 15(5): 930\u2013947","journal-title":"Cancer Discov"},{"issue":"4","key":"1210_CR224","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41587-025-02597-w","volume":"43","author":"X Yuan","year":"2025","unstructured":"Yuan X, Xiao Y, Yu D. Turn cold tumors hot by reprogramming the tumor microenvironment. Nat Biotechnol 2025; 43(4): 466\u2013470","journal-title":"Nat Biotechnol"},{"issue":"3","key":"1210_CR225","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 2023; 41(3): 421\u2013433","journal-title":"Cancer Cell"},{"issue":"9","key":"1210_CR226","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","volume":"25","author":"CJ Imianowski","year":"2025","unstructured":"Imianowski CJ, Chen Q, Workman CJ, Vignali DAA. Regulatory T cells in the tumour microenvironment. Nat Rev Cancer 2025; 25(9): 703\u2013722","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1210_CR227","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol 2024; 21(2): 147\u2013164","journal-title":"Nat Rev Clin Oncol"},{"key":"1210_CR228","doi-asserted-by":"publisher","first-page":"1403771","DOI":"10.3389\/fimmu.2024.1403771","volume":"15","author":"M M\u00f6ller","year":"2024","unstructured":"M\u00f6ller M, Orth V, Umansky V, Hetjens S, Braun V, Rei\u00dffelder C, Hardt J, Seyfried S. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis. Front Immunol 2024; 15: 1403771","journal-title":"Front Immunol"},{"issue":"11","key":"1210_CR229","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.immuni.2022.10.002","volume":"55","author":"BG Nixon","year":"2022","unstructured":"Nixon BG, Kuo F, Ji L, Liu M, Capistrano K, Do M, Franklin RA, Wu X, Kansler ER, Srivastava RM, Purohit TA, Sanchez A, Vuong L, Krishna C, Wang X, Morse Iii HC, Hsieh JJ, Chan TA, Murphy KM, Moon JJ, Hakimi AA, Li MO. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity 2022; 55(11): 2044\u20132058.e5","journal-title":"Immunity"},{"issue":"1","key":"1210_CR230","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"J Waibl Polania","year":"2025","unstructured":"Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E, Woroniecka K, Finlay JB, Ayasoufi K, Fecci PE. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity 2025; 58(1): 232\u2013246.e6","journal-title":"Immunity"},{"issue":"9","key":"1210_CR231","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ccell.2024.08.011","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, de Souza N, Bodenmiller B. Classifying cancer-associated fibroblasts\u2014the good, the bad, and the target. Cancer Cell 2024; 42(9): 1480\u20131485","journal-title":"Cancer Cell"},{"issue":"1","key":"1210_CR232","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-025-03387-7","volume":"44","author":"F Weber","year":"2025","unstructured":"Weber F, Reese KL, Pantel K, Smit DJ. Cancer-associated fibroblasts as a potential novel liquid biopsy marker in cancer patients. J Exp Clin Cancer Res 2025; 44(1): 127","journal-title":"J Exp Clin Cancer Res"},{"issue":"19","key":"1210_CR233","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9 J, Sheppard D. TGF-\u03b2 signaling in health and disease. Cell 2023; 186(19): 4007\u20134037","journal-title":"Cell"},{"issue":"4","key":"1210_CR234","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2023.12.015","volume":"80","author":"AM Shiri","year":"2024","unstructured":"Shiri AM, Zhang T, Bedke T, Zazara DE, Zhao L, L\u00fccke J, Sabihi M, Fazio A, Zhang S, Tauriello DVF, Batlle E, Steglich B, Kempski J, Agalioti T, Nawrocki M, Xu Y, Riecken K, Liebold I, Brockmann L, Konczalla L, Bosurgi L, Mercanoglu B, Seeger P, K\u00fcsters N, Lykoudis PM, Heumann A, Arck PC, Fehse B, Busch P, Grotel\u00fcschen R, Mann O, Izbicki JR, Hackert T, Flavell RA, Gagliani N, Giannou AD, Huber S. IL- 10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction. J Hepatol 2024; 80(4): 634\u2013644","journal-title":"J Hepatol"},{"issue":"4","key":"1210_CR235","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 2022; 19(4): 237\u2013253","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1210_CR236","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.cell.2020.10.007","volume":"183","author":"SH Shrager","year":"2020","unstructured":"Shrager SH, Kiel C. SnapShot: APC\/T cell immune checkpoints. Cell 2020; 183(4): 1142\u20131142.e1","journal-title":"Cell"},{"key":"1210_CR237","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jconrel.2020.06.029","volume":"326","author":"A Huang","year":"2020","unstructured":"Huang A, Pressnall MM, Lu R, Huayamares SG, Griffin JD, Groer C, DeKosky BJ, Forrest ML, Berkland CJ. Human intratumoral therapy: linking drug properties and tumor transport of drugs in clinical trials. J Control Release 2020; 326: 203\u2013221","journal-title":"J Control Release"},{"issue":"11","key":"1210_CR238","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","volume":"20","author":"E Kon","year":"2023","unstructured":"Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol 2023; 20(11): 739\u2013754","journal-title":"Nat Rev Clin Oncol"},{"issue":"807","key":"1210_CR239","doi-asserted-by":"publisher","first-page":"eadk1868","DOI":"10.1126\/scitranslmed.adk1868","volume":"17","author":"E Quijano","year":"2025","unstructured":"Quijano E, Martinez-Saucedo D, Ianniello Z, Pinto-Medici N, Rackear M, Chen H, Lola-Pereira L, Liu Y, Hegan D, Shan X, Tseng R, Yugawa D, Chowdhury S, Khang M, Singh JP, Abdullah R, Azhir P, Kashima S, Woods WS, Gosstola N, Turner BC, Squinto S, Ludwig DL, Bindra RS, Robert ME, Braun DA, Perez Pinera P, Saltzman WM, Escobar-Hoyos LF, Glazer PM. Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer. Sci Transl Med 2025; 17(807): eadk1868","journal-title":"Sci Transl Med"},{"issue":"3","key":"1210_CR240","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3390\/cancers15030724","volume":"15","author":"HY Tanaka","year":"2023","unstructured":"Tanaka HY, Nakazawa T, Enomoto A, Masamune A, Kano MR. Therapeutic strategies to overcome fibrotic barriers to nanomedicine in the pancreatic tumor microenvironment. Cancers (Basel) 2023; 15(3): 724","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1210_CR241","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, Tong R, Miao YB, Cai L. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther 2023; 8(1): 418","journal-title":"Signal Transduct Target Ther"},{"issue":"470","key":"1210_CR242","doi-asserted-by":"publisher","first-page":"eaau5516","DOI":"10.1126\/scitranslmed.aau5516","volume":"10","author":"CM Laumont","year":"2018","unstructured":"Laumont CM, Vincent K, Hesnard L, Audemard \u00c9, Bonneil \u00c9, Laverdure JP, Gendron P, Courcelles M, Hardy MP, C\u00f4t\u00e9 C, Durette C, St-Pierre C, Benhammadi M, Lanoix J, Vobecky S, Haddad E, Lemieux S, Thibault P, Perreault C. Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med 2018; 10(470): eaau5516","journal-title":"Sci Transl Med"}],"container-title":["MedScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1210-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-026-1210-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1210-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:01:49Z","timestamp":1778137309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-026-1210-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":242,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s11684-026-1210-6","relation":{},"ISSN":["3091-4973","3091-4981"],"issn-type":[{"value":"3091-4973","type":"print"},{"value":"3091-4981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest\n                      Niu Qiao, Jing-Xian Chen, Yan Liu, and Zhu Chen declare no competing interests. Sai-Juan Chen is the Editor-in-Chief of\n                      MedScience\n                      and was excluded from peer review and all editorial decisions related to the acceptance and publication of this article. Peer review was handled independently by other editors to minimize bias.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}